MR
Michael Rome
VCManaging Director, Foresite Capital
Oncology and precision medicine therapeutics investor
San Francisco, CA3 notable investments
Series ASeries B+
BioHealthcare
Background
Michael Rome is a Managing Director at Foresite Capital who joined the firm in 2016 and leads its therapeutics investing practice. He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and a PhD in Biochemistry from Caltech as an NSF Fellow. His investment focus spans oncology, inflammation, and precision medicine. Notable exits include XinThera (acquired by Gilead), Affinivax (acquired by GSK), and Turning Point Therapeutics (acquired by BMS for $4.1 billion).
Investment Thesis
Precision medicine and oncology therapeutics where deep science can deliver high-value clinical differentiation.
Investment Focus
Stages
Series ASeries B+
Sectors
BioHealthcare
Based in: San Francisco, CA (North America)
Notable Investments
Last updated: Jun 11, 2026